undamentalytics Newsletter
Sign in

P3 Health Partners Inc. (PIII) stock

Add to watchlist

Add holding +

NASDAQ: PIII Nasdaq Health Care Services Next results ~November 9, 2026

C Fundamentals grade

P3 Health Partners Inc. is a US-listed company in the health care services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$12

Price-to-sales vs peers

Base case. Range ~$12–$1000. Sales per share times peers' typical price-to-sales; used only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

P3 Health Partners Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 1 selling0 purchases and 3 sales by directors and officers, last 12 monthsInsider trades
  • Funds10 adding, 9 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter P3 Health Partners files

Where P3 Health Partners stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $1.50bn, up 2.8% on a year earlier, against a decline of 0.9% a quarter earlier. That puts it 19 of 21 for growth among the health care services companies we cover. Free-cash-flow margin held at -8.7%. Operating margin widened to -9.9% from -21.7%. The diluted share count is up 40.0% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 1 of our 6 financial-health checks. Our revenue-to-maturity cash-flow model value is $42.34 a share, against a share price of $4.00.

Source: 10-Q filed August 10, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

P3 Health Partners Inc.'s trailing-twelve-month revenue grew 2.8% year on year, with a free-cash-flow margin of -8.7%. Where it stands out: stock pay as % of revenue of 0.3% ranks 3 of 35 health care services companies we cover. Where it lags: change in share count of 40.0% ranks 36 of 39 health care services companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 0.4% while net income grew 32.6%: a 33pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Growth speeding up. The growth rate is 3.7 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 11.8 points on a year ago.

Things to watch

  • Results due soon. Results are expected around 13 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -9.9%: costs exceed revenue.
  • Burning cash. Free cash flow was -8.7% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 40.0% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 219% and a beta of -1.4 against the S&P 500.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results: FY2026 Q2

Filed August 10, 2026
Earnings per share
-$0.63 against an average estimate of -$1.90: beat by 66.8%
Revenue
$386m, up 8.6% on a year earlier
Share reaction
+6.8% in the first session after the results on August 10, 2026, against -0.3% for the S&P 500
Next report
November 9, 2026

P3 Health Partners' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.7%
  • 1 week+3.1%
  • 1 month-37.1%
  • This year+14.6%
  • 1 year-54.3%
  • 5 years-99.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.5B
Operating margin
-9.9%
Net margin
-6.6%
EPS (TTM, diluted)
$-21.48

Growth

Revenue growth
+2.8%
Change in growth rate
+3.7 pts
Share count change
+40.0%

Cash

Free cash flow (TTM)
-$131M
FCF margin
-8.7%
Stock pay % of revenue
0.3%

Earnings

Last results
August 10, 2026
Next results (est.)
November 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Agreement
  3. Results
  4. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

P3 Health Partners Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value P3 Health Partners Inc. as an operating company, with every model that fits that kind of business. Cost of equity 7.6%: the 10-year Treasury yield (4.9%) plus a beta of 0.6 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$12 ~$210–$1000 Included, half weight
Cash-flow model (DCF) Free cash flow after stock pay, grown then faded to 2.5%, discounted at 8.5%. — Does not apply: Noncontrolling ownership is material. Its fair value and share of cash flow must be valued separately; a book-value deduction is insufficient.
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: Noncontrolling ownership is material. Its fair value and share of cash flow must be valued separately; a book-value deduction is insufficient.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: Noncontrolling ownership is material. Its fair value and share of cash flow must be valued separately; a book-value deduction is insufficient.
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$12 ~$12–$1000 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare P3 Health Partners Inc. with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2022202320242025Now
Share price$92.00$70.50$11.25$3.49$4.00
Market value$38m$208m$33m$11m$18m
+ Net debt (− = net cash)$77m$73m$159m$312m$99m
Enterprise value$116m$280m$192m$323m$117m
Multiples
Price / sales 0.0x0.2x0.0x0.0x0.0x
Price / earnings —————
Price / free cash flow —————
EV / EBITDA —————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, after the close. Analysts expect revenue of $385m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$14.84 +67% $1.6bn +6%
Next −$13.88 +7% $1.7bn +9%

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$1.90 −$0.63 +66.8%
Mar 2026 −$3.50 $0.32 +109.1%
Dec 2025 −$9.46 −$23.02 −143.2%
Sept 2025 −$6.04 −$9.67 −60.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

2 analysts, Oct 2026
Buy150%
Hold150%
Sell00%

Monthly trend

  1. Oct 2026112
  2. Sep 2026112

Counts of recommendations published by analysts covering P3 Health Partners Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
0.4%
of tradable shares
Days to cover
0.85
at average volume
Short interest, 1 month
−48%
to September 30, 2026
Held by institutions
8%
of shares
Held by insiders
48.4%
of shares
Employees
320
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −54.3%

$8.75 on October 31, 2025 to $4.00

ThenNowEffect
Revenue (last 12 months) $1.5bn $1.5bn +2.8%
P/S multiple 0.0x 0.0x −37.7%
Share count 3m 5m −28.6%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
PIII−74%−23%−84%−69%+15%
Industry peers (median)−25%+8%−6%−6%+15%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
PIII42%25%8%42%27%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
PIII−80%−80%−87%−72%−77%
S&P 500−25%−10%−8%−19%−9%

Worst fall since April 6, 2021: 100% from December 10, 2021 to February 2, 2026. Getting back needed a 37532% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.52 – $16.47
From 52-week high
−75.7%
vs 50-day average
−39.5%
vs 200-day average
−38.9%
Volatility (1 year)
219%
Beta vs S&P 500
-1.38

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±25.9%
After a week
2 up, 10 down
typical move ±36.8%
After a month
2 up, 10 down
typical move ±42.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 10, 2026 +6.8% −0.3% −8.7% −27.3%
May 14, 2026 +216.2% −0.4% +288.2% +227.5%
March 26, 2026 −5.5% −3.5% −17.4% −13.2%
November 14, 2025 −14.6% −0.9% −18.4% −34.5%
August 14, 2025 −4.6% −0.2% +3.0% +21.5%
May 15, 2025 −2.3% +1.1% −7.0% −20.5%
March 27, 2025 −2.8% −2.3% −2.2% −0.4%
November 12, 2024 −36.9% −0.3% −46.7% −46.0%
August 7, 2024 −2.5% +1.6% −2.6% −24.1%
May 8, 2024 +2.5% +0.6% −14.0% −21.6%
March 28, 2024 −13.2% −0.2% −20.9% −54.1%
January 10, 2024 −3.0% +0.5% −11.9% −18.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

P3 Health Partners Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) P3 Health Partners Inc.
$1.1B $1.2B $1.3B $1.4B $1.5B $1.6B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $1.2B Revenue (TTM), FY23 Q4: $1.3B Revenue (TTM), FY24 Q1: $1.4B Revenue (TTM), FY24 Q2: $1.4B Revenue (TTM), FY24 Q3: $1.5B Revenue (TTM), FY24 Q4: $1.5B Revenue (TTM), FY25 Q1: $1.5B Revenue (TTM), FY25 Q2: $1.5B Revenue (TTM), FY25 Q3: $1.4B Revenue (TTM), FY25 Q4: $1.5B Revenue (TTM), FY26 Q1: $1.5B Revenue (TTM), FY26 Q2: $1.5B $1.5B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $1.2B
FY23 Q4 $1.3B
FY24 Q1 $1.4B
FY24 Q2 $1.4B
FY24 Q3 $1.5B
FY24 Q4 $1.5B
FY25 Q1 $1.5B
FY25 Q2 $1.5B
FY25 Q3 $1.4B
FY25 Q4 $1.5B
FY26 Q1 $1.5B
FY26 Q2 $1.5B
Revenue growth, TTM YoY P3 Health Partners Inc.
-10% 0% 10% 20% 30% FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue growth, TTM YoY, FY23 Q4: 20.7% Revenue growth, TTM YoY, FY24 Q1: 25.5% Revenue growth, TTM YoY, FY24 Q2: 23.3% Revenue growth, TTM YoY, FY24 Q3: 25.4% Revenue growth, TTM YoY, FY24 Q4: 18.5% Revenue growth, TTM YoY, FY25 Q1: 9.8% Revenue growth, TTM YoY, FY25 Q2: 4.2% Revenue growth, TTM YoY, FY25 Q3: -2.1% Revenue growth, TTM YoY, FY25 Q4: -2.8% Revenue growth, TTM YoY, FY26 Q1: -0.9% Revenue growth, TTM YoY, FY26 Q2: 2.8% 2.8%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 20.7%
FY24 Q1 25.5%
FY24 Q2 23.3%
FY24 Q3 25.4%
FY24 Q4 18.5%
FY25 Q1 9.8%
FY25 Q2 4.2%
FY25 Q3 -2.1%
FY25 Q4 -2.8%
FY26 Q1 -0.9%
FY26 Q2 2.8%
Operating margin (TTM) P3 Health Partners Inc.
-60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -54.4% Operating margin (TTM), FY23 Q4: -13.3% Operating margin (TTM), FY24 Q1: -12.0% Operating margin (TTM), FY24 Q2: -12.3% Operating margin (TTM), FY24 Q3: -16.7% Operating margin (TTM), FY24 Q4: -21.4% Operating margin (TTM), FY25 Q1: -21.2% Operating margin (TTM), FY25 Q2: -21.7% Operating margin (TTM), FY25 Q3: -17.6% Operating margin (TTM), FY25 Q4: -18.5% Operating margin (TTM), FY26 Q1: -15.2% Operating margin (TTM), FY26 Q2: -9.9% -9.9%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -54.4%
FY23 Q4 -13.3%
FY24 Q1 -12.0%
FY24 Q2 -12.3%
FY24 Q3 -16.7%
FY24 Q4 -21.4%
FY25 Q1 -21.2%
FY25 Q2 -21.7%
FY25 Q3 -17.6%
FY25 Q4 -18.5%
FY26 Q1 -15.2%
FY26 Q2 -9.9%
FCF margin (TTM) P3 Health Partners Inc.
-10% -5% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -8.0% FCF margin (TTM), FY23 Q4: -6.1% FCF margin (TTM), FY24 Q1: -5.4% FCF margin (TTM), FY24 Q2: -3.8% FCF margin (TTM), FY24 Q3: -4.6% FCF margin (TTM), FY24 Q4: -7.3% FCF margin (TTM), FY25 Q1: -8.3% FCF margin (TTM), FY25 Q2: -8.9% FCF margin (TTM), FY25 Q3: -8.5% FCF margin (TTM), FY25 Q4: -6.3% FCF margin (TTM), FY26 Q1: -5.8% FCF margin (TTM), FY26 Q2: -8.7% -8.7%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -8.0%
FY23 Q4 -6.1%
FY24 Q1 -5.4%
FY24 Q2 -3.8%
FY24 Q3 -4.6%
FY24 Q4 -7.3%
FY25 Q1 -8.3%
FY25 Q2 -8.9%
FY25 Q3 -8.5%
FY25 Q4 -6.3%
FY26 Q1 -5.8%
FY26 Q2 -8.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 145 491 579 1,049 1,266 1,500 1,459 1,503
EBITDA −39 −28 −127 −1,474 −81 −235 −186 −64
Operating income −40 −29 −129 −1,561 −168 −321 −270 −149
Net income −42 −31 −146 −270 −58 −136 −148 −98
Diluted EPS — — — −$650.00 −$63.00 −$54.06 −$45.26 −$21.48
Growth (year on year)
Revenue — +237.5% +17.8% +81.4% +20.7% +18.5% −2.8% +2.8%
Margins
EBITDA margin −26.9% −5.7% −22.0% −140.4% −6.4% −15.6% −12.8% −4.3%
Operating margin −27.2% −5.8% −22.3% −148.7% −13.3% −21.4% −18.5% −9.9%
Net margin −28.9% −6.4% −25.3% −25.7% −4.6% −9.1% −10.1% −6.6%
Free-cash-flow margin −20.4% −5.6% −9.4% −12.2% −6.1% −7.3% −6.3% −8.7%
Cash flow
Cash from operations −28 −25 −51 −126 −76 −110 −91 −131
Capital spending 1 3 3 2 2 0 0 0
Free cash flow −30 −28 −54 −128 −78 −110 −91 −131
Stock-based pay 0 0 4 19 6 6 6 4
Free cash flow after stock pay −30 −28 −58 −148 −84 −116 −97 −135
Balance sheet
Cash 33 36 — 18 36 39 25 21
Total debt 17 55 — 95 109 198 337 120
Net debt (negative = net cash) −16 19 — 77 73 159 312 99
Diluted shares — — — — 3m 3m 3m 5m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 6 checks passed · June 30, 2026
What it owns · $654m
Short-term assets $179mLonger-term assets $475m
What it owes, and who funded it · $590m
Short-term liabilities $389mLonger-term liabilities $128mShareholders' equity $73m
  • Short-term assets cover short-term liabilities $179m of assets due within a year against $389m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $179m short-term assets against $128m of longer-dated liabilities.
  • More cash than debt $21m of cash against $120m of debt.
  • Debt below 40% of shareholders' equity Debt is 164% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 29% to 164% over five years.
  • A year's operating cash flow covers at least 20% of debt −$131m of operating cash flow against $120m of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From P3 Health Partners Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+40.0%
year over year

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated PIII ADUS HQY PGNY GH PNTG Median
Revenue, last 12 months $1.5bn $1.5bn $1.4bn $1.3bn $1.2bn $1.1bn $1.2bn
Revenue growth, last 12 months 2.8% 15.9% 7.3% 5.5% 42.7% 37.9% 7.3%
Revenue growth, 3-year average 9.7% 13.9% 13.2% 11.0% 32.4% 30.0% 11.3%
Revenue growth, latest quarter 8.6% 8.0% 7.6% 5.3% 44.3% 35.8% 8.5%
Gross margin — 32.4% 71.2% 24.6% 65.0% — 27.9%
Operating margin −9.9% 10.0% 25.8% 8.6% −39.7% 5.6% 2.3%
Operating margin, 3-year average −14.7% 9.4% 19.9% 7.0% −58.3% 5.5% 2.3%
Net margin −6.6% 7.1% 17.4% 6.0% −38.3% 2.9% 1.2%
Cash from operations / revenue −8.7% 11.0% 36.0% 15.4% −15.7% 4.8% 6.1%
Free-cash-flow margin −8.7% 10.5% 35.8% 13.6% −20.3% 3.1% 5.1%
Free-cash-flow margin, 3-year average −7.1% 8.9% 30.8% 14.7% −33.2% 3.5% 3.6%
Stock pay / revenue 0.3% 1.2% 6.0% 8.2% 16.2% 0.9% 1.1%
Change in share count 40.0% 0.8% −3.3% −4.2% 4.6% 3.6% 0.3%

Median of all 41 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

41 health care services companies
Measure Company Peer median Rank
Revenue growth Growth 2.8% 7.3% 29 of 41
Change in growth rate Growth +3.7pp +1.1pp 10 of 41
Operating margin Profitability -9.9% 2.6% 31 of 40
Net margin Profitability -6.6% 1.2% 31 of 41
Free-cash-flow margin Cash generation -8.7% 5.1% 34 of 40
Stock pay as % of revenue Cash generation 0.3% 0.9% 3 of 35
Long-term debt as % of assets Balance sheet 15.0% 27.7% 10 of 31
Change in share count Balance sheet 40.0% 0.4% 36 of 39

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Capitated Revenue $1.4B ▼ 3.7%
Health Care Patient Service $30.1M ▲ 78.6%
Health Care Other $30.1M ▲ 78.6%
Health Care Incentive Fees $16.2M ▲ 4456.7%
Health Care Care Coordination Management Fees $10.8M ▲ 2.5%
Health Care Clinical Fees Insurance Revenue $3.1M ▼ 48.5%

These categories overlap or exclude eliminations, so shares aren't shown.

From P3 Health Partners Inc.'s 10-K filed March 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$3.1M
Institutions reporting
19
Shares held vs prior quarter
▲ 33.4%
Positions opened / closed
8 / 4

Top buyers and sellers, Q2 2026: 10 institutions bought and 9 sold ; the biggest buyer was Jane Street Group, LLC (+54K shares) and the biggest seller Vanguard Capital Management LLC (−29K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
HRT Financial LP $590,000 55K 18.9% ▲ 262.6%
Jane Street Group, LLC $588,546 54K 18.9% New
Vanguard Capital Management LLC $448,027 41K 14.4% ▼ 41.3%
Myda Advisors LLC $216,000 20K 6.9% New
Corient Private Wealth LP $213,160 20K 6.8% ▼ 0.5%
Geode Capital Management, LLC $184,654 17K 5.9% ▼ 34.0%
Scientech Research LLC $176,234 16K 5.7% New
Abundance Wealth Counselors $172,800 16K 5.5% New
Renaissance Technologies LLC $163,609 15K 5.2% New
Diversified Trust Co $145,152 13K 4.7% ▼ 33.8%
Blackrock, Inc. $82,480 8K 2.6% ▼ 30.1%
Vanguard Fiduciary Trust Co $69,952 6K 2.2% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not P3 Health Partners Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $823,927 3 trades by 1 insider · 0% under pre-set plans
Net ▼ $823,927 net selling
Insider Date Trade Shares Price Value
Hudson Vegas Investment Manager, Llc 10% owner August 10, 2026 Sell 19,074 $16.05 $306,138
Hudson Vegas Investment Manager, Llc 10% owner August 10, 2026 Sell 1,041 $13.38 $13,929
Hudson Vegas Investment Manager, Llc 10% owner August 10, 2026 Sell 29,885 $16.86 $503,861

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 13, 2026 estimated from the company's past filing pattern, not announced

  • August 10, 2026
  • May 14, 2026
  • March 26, 2026
  • November 14, 2025
  • August 14, 2025
  • May 15, 2025

Recent SEC filings

Data status

When each part of this page on P3 Health Partners Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

P3 Health Partners Inc. in brief

What does P3 Health Partners Inc. do?
P3 Health Partners Inc. is a US-listed company in the health care services industry. Its financial year ends in December.
What is P3 Health Partners Inc.'s stock ticker?
P3 Health Partners Inc. trades under the ticker PIII on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is P3 Health Partners Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, P3 Health Partners Inc. reported revenue of $1.5B, 2.8% higher than a year earlier, according to its SEC filings.
What is P3 Health Partners Inc.'s free cash flow?
P3 Health Partners Inc.'s free-cash-flow margin is -8.7% of revenue over the trailing twelve months, ranking 34 of the 40 health care services companies we cover.
Who are P3 Health Partners Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are HRT Financial LP, Jane Street Group, LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is P3 Health Partners Inc.'s market cap?
On November 2, 2026, P3 Health Partners Inc.'s market capitalisation was about $18.3M and net debt of $99M. Market figures come from third-party market data and may be delayed.
How much debt does P3 Health Partners Inc. have?
P3 Health Partners Inc.'s debt-to-equity ratio is 163.8%, from its latest balance sheet (29.2% five years earlier). The financial health section below sets out its other solvency checks.
Who are P3 Health Partners Inc.'s competitors?
In our Health Care Services peer group, the companies closest to P3 Health Partners Inc. are Addus Homecare Corp, Healthequity, Inc., Progyny, Inc., Guardant Health, Inc. and Pennant Group, Inc. The side-by-side comparison below sets their revenue, margins and growth against P3 Health Partners Inc.'s.
Are insiders buying or selling P3 Health Partners Inc. stock?
Over the last 12 months, P3 Health Partners Inc.'s directors and officers reported 0 open-market purchases and 3 sales on Form 4. The insider trading page charts every trade.
When is P3 Health Partners Inc.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — P3 Health Partners Inc. announces its own schedule.